Semin Thromb Hemost 2013; 39(05): 469-476
DOI: 10.1055/s-0033-1343887
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombosis in Nephrotic Syndrome

Biagio Barbano
1   Department of Clinical Medicine, Nephrology Unit, Sapienza University of Rome, Rome, Italy
,
Antonietta Gigante
1   Department of Clinical Medicine, Nephrology Unit, Sapienza University of Rome, Rome, Italy
,
Antonio Amoroso
1   Department of Clinical Medicine, Nephrology Unit, Sapienza University of Rome, Rome, Italy
,
Rosario Cianci
1   Department of Clinical Medicine, Nephrology Unit, Sapienza University of Rome, Rome, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. April 2013 (online)

Abstract

Nephrotic syndrome (NS) is characterized by heavy proteinuria, edema, hypoalbuminemia, and hyperlipidemia and the most frequent causes are glomerular diseases. An uncommon presentation is iatrogenic NS, an adverse effect of some drugs administration. In the clinical course of NS, a typical feature is dysregulated coagulation state, promoted by the breakdown of permselectivity barrier of the glomerular capillary wall, resulting in the leakage of high-molecular-mass proteins, at least the size of albumin. This hypercoagulable condition is supported by several factors, such as abnormalities in platelet activation and an imbalance between anticoagulation/antithrombosis and procoagulant/prothrombotic mechanisms. Thus, NS and the risk of developing thromboses are strictly related. Thrombotic events affect the venous system rather than arterial vessels with different features and frequencies. Deep venous system of the lower extremities and renal veins are the most frequent source of pulmonary embolism, the most dangerous NS complication. Prophylactic anticoagulation and thrombosis treatment are not clearly established because large randomized trials and guidelines are lacking. The management of NS and the decision of when and how to anticoagulate the patient represent a teamwork challenge for physicians.

 
  • References

  • 1 Nachman PH, Jennette JC, Falk RJ. Primary glomerular disease. In: Brenner BM, , ed. Brenner and Rector's The Kidney. 8th ed. Philadelphia, PA: Saunders; 2007: 987-1042
  • 2 Rostoker G, Behar A, Lagrue G. Vascular hyperpermeability in nephrotic edema. Nephron 2000; 85 (3) 194-200
  • 3 Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism. Br J Clin Pharmacol 1999; 47 (2) 203-210
  • 4 Galesic K, Ljubanovic D, Bulimbasic S, Racic I. Minimal change disease and acute tubular necrosis caused by diclofenac. Nephrology (Carlton) 2008; 13 (1) 87-88
  • 5 Habib GS, Saliba W, Nashashibi M, Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med 2006; 17 (5) 343-348
  • 6 Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74 (11) 1385-1393
  • 7 Barri YM, Munshi NC, Sukumalchantra S , et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004; 65 (2) 634-641
  • 8 Sakarcan A, Thomas DB, O'Reilly KP, Richards RW. Lithium-induced nephrotic syndrome in a young pediatric patient. Pediatr Nephrol 2002; 17 (4) 290-292
  • 9 Kumasaka R, Nakamura N, Shirato K , et al. Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis. Clin Exp Nephrol 2006; 10 (3) 222-225
  • 10 Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49 (2) 186-193
  • 11 George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49 (2) e23-e29
  • 12 Ponticelli C, Glassock Richard J. Treatment of Primary Glomerulonephritis. 2nd ed. New York, NY: Oxford University Press; 2009: 21-26
  • 13 Anderson S, Komers R, Brenner BM. Renal and systemic manifestations of glomerular disease. In: Brenner and Rector's The Kidney. 8th ed. Philadelphia, PA: Saunders; 2007: 821-823
  • 14 Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets 1996; 7 (3) 125-137
  • 15 Remuzzi G, Mecca G, Marchesi D , et al. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res 1979; 16 (3–4) 345-354
  • 16 Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003; 362 (9384) 629-639
  • 17 Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome: non-specific strategies for treatment. Nephrology (Carlton) 2008; 13 (1) 45-50
  • 18 Citak A, Emre S, Sâirin A, Bilge I, Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol 2000; 14 (2) 138-142
  • 19 Cherng SC, Huang WS, Wang YF, Yang SP, Lin YF. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med 2000; 25 (3) 167-172
  • 20 Ozkayin N, Mir S, Kavakli K. Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity. Int Urol Nephrol 2004; 36 (4) 599-603
  • 21 Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012; 7 (3) 513-520
  • 22 Vigano-D'Angelo S, D'Angelo A, Kaufman Jr CE, Sholer C, Esmon CT, Comp PC. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987; 107 (1) 42-47
  • 23 Al-Mugeiren MM, Abdel Gader AG, Al-Rasheed SA, Al-Salloum AA. Tissue factor pathway inhibitor in childhood nephrotic syndrome. Pediatr Nephrol 2006; 21 (6) 771-777
  • 24 Castellino P, Cataliotti A. Changes of protein kinetics in nephrotic patients. Curr Opin Clin Nutr Metab Care 2002; 5 (1) 51-54
  • 25 Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?. Nephron 1993; 63 (3) 249-254
  • 26 Jensen H, Rossing N, Andersen SB, Jarnum S. Albumin metabolism in the nephrotic syndrome in adults. Clin Sci 1967; 33 (3) 445-457
  • 27 Yssing M, Jensen H, Jarnum S. Albumin metabolism and gastrointestinal protein loss in children with nephrotic syndrome. Acta Paediatr Scand 1969; 58 (2) 109-115
  • 28 de Sain-van der Velden MG, Kaysen GA, de Meer K , et al. Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes. Kidney Int 1998; 53 (1) 181-188
  • 29 Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007; 13 (16) 1647-1659
  • 30 Milionis HJ, Liberopoulos E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol 2005; 99 (2) 269-275
  • 31 Levenson J, Giral P, Megnien JL, Gariepy J, Plainfosse MC, Simon A. Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hypercholesterolemic men. Arterioscler Thromb Vasc Biol 1997; 17 (1) 45-50
  • 32 Fowkes FG, Lowe GD, Housley E , et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342 (8863) 84-86
  • 33 Kanfer A, Kleinknecht D, Broyer M, Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh 1970; 24 (3) 562-571
  • 34 Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28 (3) 429-439
  • 35 Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23 (3) 271-280
  • 36 Kuipers S, Cannegieter SC, Doggen CJ, Rosendaal FR. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood 2009; 113 (9) 2064-2069
  • 37 Tsai AW, Cushman M, Rosamond WD , et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113 (8) 636-642
  • 38 Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006; 118 (3) 397-407
  • 39 Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998; 338 (17) 1202-1211
  • 40 Remuzzi G, Marchesi D, Mecca G, de Gaetano G, Silver M. Platelet hypersensitivity in the nephrotic syndrome. Proc Eur Dial Transplant Assoc 1979; 16: 487-494
  • 41 Walter E, Deppermann D, Andrassy K, Koderisch J. Platelet hyperaggregability as a consequence of the nephrotic syndrome. Thromb Res 1981; 23 (6) 473-479
  • 42 Sirolli V, Ballone E, Garofalo D , et al. Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron 2002; 91 (3) 424-430
  • 43 Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest 1994; 93 (1) 204-211
  • 44 Soulat T, Loyau S, Baudouin V , et al. Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: an in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler Thromb Vasc Biol 2000; 20 (2) 575-584
  • 45 Svenningsen P, Bistrup C, Friis UG , et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009; 20 (2) 299-310
  • 46 Thomson C, Forbes CD, Prentice CR, Kennedy AC. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med 1974; 43 (171) 399-407
  • 47 Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46 (2) 287-296
  • 48 Yoshida Y, Shiiki H, Iwano M , et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron 2001; 88 (1) 24-29
  • 49 Radhakrishnan J. Venous thromboembolism and membranous nephropathy: so what's new?. Clin J Am Soc Nephrol 2012; 7 (1) 3-4
  • 50 Dangas G, Mehran R, Harpel PC , et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32 (7) 2035-2042
  • 51 Yoshida Y, Shiiki H, Iwano M , et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron 2001; 88 (1) 24-29
  • 52 Jennette JC, Olson JL, Schwartz MM , et al. Heptinstall's Pathology of the Kidney. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 126-149
  • 53 Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18 (8) 2221-2225
  • 54 Htike N, Superdock K, Thiruveedi S, Surkis W, Teehan G. Evaluating proteinuria and nephrotic syndrome in patients with venous thromboembolism. Am J Med Sci 2012; 343 (2) 124-126
  • 55 Mahmoodi BK, ten Kate MK, Waanders F , et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117 (2) 224-230
  • 56 Ulinski T, Guigonis V, Baudet-Bonneville V, Auber F, Garcette K, Bensman A. Mesenteric thrombosis causing short bowel syndrome in nephrotic syndrome. Pediatr Nephrol 2003; 18 (12) 1295-1297
  • 57 Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980; 69 (6) 819-827
  • 58 Wagoner RD, Stanson AW, Holley KE, Winter CS. Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance. Kidney Int 1983; 23 (2) 368-374
  • 59 Velasquez Forero F, Garcia Prugue N, Ruiz Morales N. Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 1988; 8 (6) 457-462
  • 60 Cameron JS. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol Necker Hosp 1984; 13: 75-114
  • 61 Egli F, Elmiger P, Stalder G. Thrombose als Komplikation des nephrotischen Syndroms [Thrombosis as a complication of nephrotic syndrome]. Helv Paediatr Acta 1973; 30 (Suppl): 20-21
  • 62 Appenzeller S, Zeller CB, Annichino-Bizzachi JM , et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg 2005; 107 (5) 371-378
  • 63 Lionaki S, Derebail VK, Hogan SL , et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 2012; 7 (1) 43-51
  • 64 Gigante A, Barbano B, Sardo L , et al. Hypercoagulability and nephrotic syndrome. Curr Vasc Pharmacol 2012; (e-pub ahead of print)
  • 65 Zhang LJ, Wang ZJ, Zhou CS, Lu L, Luo S, Lu GM. Evaluation of pulmonary embolism in pediatric patients with nephrotic syndrome with dual energy CT pulmonary angiography. Acad Radiol 2012; 19 (3) 341-348
  • 66 Sullivan III MJ, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76 (8) 1011-1016
  • 67 Igarashi M, Roy III S, Stapleton FB. Cerebrovascular complications in children with nephrotic syndrome. Pediatr Neurol 1988; 4 (6) 362-365
  • 68 Ueda N, Kawaguchi S, Niinomi Y , et al. Effect of corticosteroids on coagulation factors in children with nephrotic syndrome. Pediatr Nephrol 1987; 1 (3) 286-289
  • 69 Brater DC. Mechanism of action of diuretics. 2012, available at http://www.uptodate.com/contents/mechanism-of-action-of-diuretics
  • 70 Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med 2008; 121 (3) 226-230
  • 71 Zhang LJ, Wang ZJ, Zhou CS, Lu L, Luo S, Lu GM. Evaluation of pulmonary embolism in pediatric patients with nephrotic syndrome with dual energy CT pulmonary angiography. Acad Radiol 2012; 19 (3) 341-348
  • 72 Kerlin BA, Blatt NB, Fuh B , et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009; 155 (1) 105-110 , e1
  • 73 Lefaucheur C, Stengel B, Nochy D , et al; GN-PROGRESS Study Group. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006; 70 (8) 1510-1517
  • 74 Beck Jr LH. Membranous nephropathy and malignancy. Semin Nephrol 2010; 30 (6) 635-644
  • 75 Mismetti P, Quenet S, Levine M , et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005; 128 (4) 2203-2210
  • 76 Lai S, Barbano B, Cianci R , et al. Rischio emorragico nell'utilizzo di eparina a basso peso molecolare nel paziente nefropatico. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure]. G Ital Nefrol 2010; 27 (6) 649-654
  • 77 Radhakrishnan J. Renal vein thrombosis and hypercoagulable state in nephrotic syndrome. 2012, available at http://www.uptodate.com/contents/renal-vein-thrombosis-and-hypercoagulable-state-in-nephrotic-syndrome
  • 78 Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012; 43 (1) 271-279
  • 79 Hohnloser SH, Oldgren J, Yang S , et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125 (5) 669-676
  • 80 Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72 (13) 1739-1753
  • 81 Markowitz GS, Brignol F, Burns ER, Koenigsberg M, Folkert VW. Renal vein thrombosis treated with thrombolytic therapy: case report and brief review. Am J Kidney Dis 1995; 25 (5) 801-806
  • 82 Paraskevas KI, Bessias N, Perdikides TP, Mikhailidis DP. Statins and venous thromboembolism: a novel effect of statins?. Curr Med Res Opin 2009; 25 (7) 1807-1809
  • 83 Resh M, Mahmoodi BK, Navis GJ, Veeger NJ, Lijfering WM. Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thromb Res 2011; 127 (5) 395-399
  • 84 Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295 (3) 306-313
  • 85 Glynn RJ, Ridker PM, Goldhaber SZ, Buring JE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007; 147 (8) 525-533
  • 86 Akoglu H, Agbaht K, Piskinpasa S , et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant 2012; 27 (4) 1460-1466
  • 87 Tholl U, Anlauf M, Helmchen U. Clopidogrel and membranous nephropathy. Lancet 1999; 354 (9188) 1443-1444